Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neuroblastoma 6Glioblastoma 6Melanoma 5Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pathologic Complete Response 2Ovarian Neoplasms 2Osteosarcoma 2Lung Neoplasms 2Liver Neoplasms 2Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Wilms Tumor 1Vaccinia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

Carboplatin 71Etoposide 63Topotecan 42Cisplatin 38pembrolizumab 30atezolizumab 26durvalumab 22Paclitaxel 16Nivolumab 14PM 01183 13rovalpituzumab tesirine 11Pemetrexed 11amrubicin 9Ipilimumab 9Injections 9Irinotecan 8AMG 757 8trilaciclib 7etoposide phosphate 6EC regimen 6Drug Therapy 6Docetaxel 6Bevacizumab 6tremelimumab 5MLN 8237 5Gemcitabine 5130-nm albumin-bound paclitaxel 5olaparib 4chiauranib 4budigalimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Carcinoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡